Saturday - May 10, 2025
WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
Upcoming Investor Events
Additionally, the company announced that its executive management team will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available, if applicable, on the investor relations section of Evolent's website, unless otherwise noted below.
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting www.evolent.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent
sfrank@evolent.com
571-895-3919 (W)
Last Trade: | US$9.05 |
Daily Change: | -1.73 -16.05 |
Daily Volume: | 4,810,665 |
Market Cap: | US$1.040B |
May 08, 2025 April 22, 2025 February 20, 2025 February 04, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load